2 Stocks Too Cheap to Ignore at These Prices
https://www.fool.com/investing/2025/06/26/2-stocks-too-cheap-to-ignore-at-these-prices/?source=iedfolrf0000001
Jun 26, 2025 -
0
5 stocks to watch on Thursday: GOOGL, INTC, PG, MRK and CMG
https://seekingalpha.com/news/4434864-5-stocks-to-watch-on-thursday-googl-intc-pg-mrk-and-cmg?source=feed_sector_healthcare
Apr 24, 2025 -
0
5 Top Stocks to Buy for March
https://www.fool.com/investing/2025/03/08/5-top-stocks-to-buy-for-march/?source=iedfolrf0000001
Mar 08, 2025 - These 5 stocks look rather intriguing at current levels.
0
The Smartest Dividend Stocks to Buy With $3,000 Right Now
https://www.fool.com/investing/2024/11/28/the-smartest-dividend-stocks-to-buy-with-3000-righ/?source=iedfolrf0000001
Nov 28, 2024 - They may not offer the very highest yields, but their dividends are built to last, and even grow.
0
Merck (MRK) Q3 2024 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2024/10/31/merck-mrk-q3-2024-earnings-call-transcript/?source=iedfolrf0000001
Oct 31, 2024 - MRK earnings call for the period ending September 30, 2024.
0
Up 700% This Year, Is It Too Late to Invest in This Stock?
https://www.fool.com/investing/2024/10/15/up-700-this-year-is-it-too-late-to-invest-in-this/?source=iedfolrf0000001
Oct 15, 2024 - The shares have experienced a pullback in the past couple of weeks.
0
Could Summit Therapeutics Become the Next Merck?
https://www.fool.com/investing/2024/10/04/could-summit-therapeutics-become-the-next-merck/?source=iedfolrf0000001
Oct 04, 2024 - Recent developments are forcing comparisons between these two drugmakers.
0
Is It Too Late to Buy ServiceNow Stock?
https://www.fool.com/investing/2024/09/20/is-it-too-late-to-buy-servicenow-stock/?source=iedfolrf0000001
Sep 20, 2024 - The stock is up nearly 60% since the beginning of the year.
0
This Company Generates No Revenue and Its Market Cap Is Over $20 Billion. Here's Why That Valuation May Not Be All That Ridiculous.
https://www.fool.com/investing/2024/09/18/this-company-generates-no-revenue-and-its-market/?source=iedfolrf0000001
Sep 18, 2024 - There's a lot of hope for ivonescimab, but are investors being a bit too bullish?
0
Corvus Stock Up on Initiation of Phase III Lymphoma Study on Lead Drug
https://www.zacks.com/stock/news/2334773/corvus-stock-up-on-initiation-of-phase-iii-lymphoma-study-on-lead-drug?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2334773
Sep 11, 2024 - CRVS stock gains 14% on initiating a registrational study on its lead candidate, soquelitinib, to treat relapsed/refractory peripheral T-cell lymphoma.
0
Page 1>